Long-term side effects of cancer treatment can stay hidden

Long-term side effects of cancer treatment do not end where a clinical-trial safety table ends. A rash, diarrhea or fatigue may receive a low toxicity grade, yet the burden changes completely when a person lives with it for months or years.

An editorial in Nature Medicine highlights a widening gap in modern oncology. Immunotherapies, antibody–drug conjugates, bispecific antibodies and other new agents are extending survival for growing numbers of patients. The methods used to record toxicity and measure its effect on daily life, however, are evolving much more slowly.

This does not mean adverse effects are ignored. The problem is which consequences enter the safety report, how long patients are followed and what researchers and clinicians describe as “manageable.”

Why a low grade does not always mean limited harm

Cancer trials commonly classify adverse events with the standardized CTCAE system. It assigns grades ranging from mild events to life-threatening complications and death, allowing therapies to be compared and dangerous reactions to be recognized quickly.

A grade, however, mainly captures the severity of an event at a particular point in time. Its duration, recurrence and cumulative effect on ordinary life may be represented far less clearly. Several days of moderate diarrhea and a year of diarrhea with the same formal grade can appear similar in a table, although they are profoundly different experiences for the patient.

The same is true of persistent rash, pain, weakness, sleep disruption, sexual problems or the need to organize daily life around treatment. These effects may not require hospitalization or qualify as severe toxicity, but they can restrict employment, relationships, physical activity and emotional well-being.

This is why the word “manageable,” often used in safety reports, does not necessarily answer the question that matters most to patients: is this condition acceptable when it continues for a long time?

The immune system can keep attacking after treatment stops

The issue is especially visible with immune checkpoint inhibitors. These drugs release molecular brakes on immune cells so that they can attack a tumor more effectively. The activated immune system can also damage healthy organs.

Immune-related complications may persist after treatment has ended. A 2023 systematic review assembled 229 publications describing 323 patients with non-endocrine immune-related adverse events lasting more than 12 weeks. The median duration was 180 days, more than half persisted beyond six months, and 30% of patients still had ongoing symptoms or treatment at the latest follow-up.

These figures cannot be used to estimate how often chronic complications occur among everyone receiving checkpoint inhibitors. Much of the evidence came from individual case reports and small series, which are more likely to feature unusual or severe events. The review nevertheless demonstrates an important point: immune toxicity is not always a brief episode that resolves when the drug is stopped.

A similar problem applies to newly developed targeted agents. The editorial uses daraxonrasib, an investigational pan-RAS inhibitor for previously treated metastatic pancreatic cancer, as an example. In a phase 3 trial, median overall survival among patients with RAS G12 mutations was 13.2 months with daraxonrasib and 6.6 months with chemotherapy. Most patients receiving the new drug developed an acne-like rash, while diarrhea and inflammation of the mouth were also reported. Full quality-of-life data had not yet been disclosed when the editorial appeared because follow-up was still short.

This does not negate the drug’s clinical benefit. It illustrates why survival and treatment burden should be assessed together rather than reported years apart.

Average safety results can conceal important differences

Even a well-run trial may provide an incomplete picture when it includes few older adults, people with multiple chronic conditions or members of particular demographic groups. Once a drug enters routine practice, it is used in patients who can differ substantially from those enrolled in registration trials.

A pooled analysis of 23,296 participants from 202 cancer trials found severe adverse events in 68.6% of women and 62.2% of men. After statistical adjustment, women had 34% higher odds of severe toxicity. The analysis did not establish why this difference occurred, and it does not mean that every cancer drug is more dangerous for every woman. It does show that a single average safety profile can obscure clinically relevant variation between groups.

Rare complications may become recognizable only after thousands of people receive a treatment. This has occurred with some skin toxicities from newer antibodies and with unusual inflammatory syndromes following cell-based therapies. Detecting and managing them requires collaboration among oncologists, immunologists, dermatologists, neurologists and other specialists rather than isolated observations within separate disciplines.

Nature Medicine argues for a broader definition of safety. Reports should capture not only the grade of an adverse effect but also its duration, recurrence and total burden. Quality-of-life and daily-functioning data should be developed with patient input and published alongside the main trial findings, rather than years after a drug is approved. Trials should also be supplemented with registries and real-world evidence, particularly for populations that were poorly represented during development.

The editorial does not provide a validated replacement for current toxicity scales, nor does it quantify how many harms are presently missed. It is an evidence-based argument built from several studies and clinical examples. Its central point is difficult to dispute: successful cancer treatment should be judged not only by how much longer a person lives, but also by how that additional time is lived.